Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $53.40

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have earned a consensus recommendation of “Moderate Buy” from the seventeen research firms that are presently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $53.50.

A number of equities research analysts recently weighed in on KYMR shares. Morgan Stanley raised their price objective on Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 6th. Oppenheimer lifted their price objective on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th. Stephens started coverage on shares of Kymera Therapeutics in a research report on Monday, November 18th. They set an “overweight” rating and a $65.00 target price for the company. Leerink Partnrs raised shares of Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Finally, Wells Fargo & Company upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $38.00 to $57.00 in a report on Monday, December 2nd.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 15.82% of the stock is currently owned by company insiders.

Institutional Trading of Kymera Therapeutics

Several large investors have recently made changes to their positions in the company. Franklin Resources Inc. boosted its stake in Kymera Therapeutics by 35.1% during the 3rd quarter. Franklin Resources Inc. now owns 29,440 shares of the company’s stock worth $1,356,000 after purchasing an additional 7,647 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Kymera Therapeutics by 7.2% in the third quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock worth $218,587,000 after buying an additional 308,954 shares in the last quarter. Quarry LP acquired a new position in Kymera Therapeutics during the third quarter worth about $95,000. HighTower Advisors LLC purchased a new stake in Kymera Therapeutics during the 3rd quarter valued at about $494,000. Finally, HighVista Strategies LLC acquired a new stake in Kymera Therapeutics in the 3rd quarter valued at about $603,000.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $46.67 on Wednesday. The stock has a market cap of $3.02 billion, a price-to-earnings ratio of -20.06 and a beta of 2.16. The firm’s 50-day moving average is $46.44 and its two-hundred day moving average is $42.47. Kymera Therapeutics has a 1 year low of $21.20 and a 1 year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. The firm had revenue of $3.74 million for the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company’s quarterly revenue was down 20.9% on a year-over-year basis. During the same period last year, the firm earned ($0.90) earnings per share. On average, equities analysts expect that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.